Effect of prophylactic doses of enoxaparin on antifactor Xa activity confirmed by rotational thromboelastometry in critically ill patients: a preliminary prospective cohort study
IntroductionCritically ill patients present multiple risk factors for venous thromboembolism (VTE). Underdosing of antithrombotic medications can result in VTE even as bleeding remains a significant concern for critically ill patients. On the other hand bleeding, remaining a significant concern for...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1498188/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527826876989440 |
|---|---|
| author | Piotr F. Czempik Piotr F. Czempik Artur Beberok |
| author_facet | Piotr F. Czempik Piotr F. Czempik Artur Beberok |
| author_sort | Piotr F. Czempik |
| collection | DOAJ |
| description | IntroductionCritically ill patients present multiple risk factors for venous thromboembolism (VTE). Underdosing of antithrombotic medications can result in VTE even as bleeding remains a significant concern for critically ill patients. On the other hand bleeding, remaining a significant concern for the critically ill, can be worsend by overdosing of antithrombotic medications. The present study aimed to assess the effects of prophylactic doses of enoxaparin on antifactor Xa activity (anti-Xa) and rotational thromboelastometry (ROTEM) parameters in critically ill patients.Materials and methodsIn this prospective single-center cohort study, the effects of enoxaparin were assessed via anti-Xa monitoring. Standard laboratory coagulation and ROTEM parameters were also determined using the same blood samples.ResultsA total of 61 patients (42.6% women) were enrolled in this study, whose median age was 59.0 (interquartile range: 43.0–70.0) years. Based on anti-Xa, the effects of enoxaparin were normal in 35 subjects (57.4%); in 17 patients (27.9%), the anti-Xa troughs and/or peaks were higher than the prophylactic range; in 9 patients (14.7%), the anti-Xa peak was lower than the prophylactic range. There were differences among the anti-Xa groups with respect to some ROTEM parameters. No VTE was detected among the study subjects. In 3 subjects (4.9%), there were signs of bleeding, and these patients presented with longer thrombin times.ConclusionAnti-Xa values may be within the prophylactic range in slightly more than half of the critically ill patients receiving enoxaparin at prophylactic doses. The dosing of low-molecular-weight heparin (LMWH) in critically ill patients may require individualization based on anti-Xa. Further studies are therefore required to establish a universal anti-Xa prophylactic range for LMWH, the timing of anti-Xa determination, and management of LMWH dosing. |
| format | Article |
| id | doaj-art-6355e8f258b04ac583a962f0c50eec19 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-6355e8f258b04ac583a962f0c50eec192025-01-15T06:10:49ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.14981881498188Effect of prophylactic doses of enoxaparin on antifactor Xa activity confirmed by rotational thromboelastometry in critically ill patients: a preliminary prospective cohort studyPiotr F. Czempik0Piotr F. Czempik1Artur Beberok2Department of Anesthesiology and Intensive Care, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, PolandTransfusion Committee, University Clinical Center of Medical University of Silesia in Katowice, Katowice, PolandDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, PolandIntroductionCritically ill patients present multiple risk factors for venous thromboembolism (VTE). Underdosing of antithrombotic medications can result in VTE even as bleeding remains a significant concern for critically ill patients. On the other hand bleeding, remaining a significant concern for the critically ill, can be worsend by overdosing of antithrombotic medications. The present study aimed to assess the effects of prophylactic doses of enoxaparin on antifactor Xa activity (anti-Xa) and rotational thromboelastometry (ROTEM) parameters in critically ill patients.Materials and methodsIn this prospective single-center cohort study, the effects of enoxaparin were assessed via anti-Xa monitoring. Standard laboratory coagulation and ROTEM parameters were also determined using the same blood samples.ResultsA total of 61 patients (42.6% women) were enrolled in this study, whose median age was 59.0 (interquartile range: 43.0–70.0) years. Based on anti-Xa, the effects of enoxaparin were normal in 35 subjects (57.4%); in 17 patients (27.9%), the anti-Xa troughs and/or peaks were higher than the prophylactic range; in 9 patients (14.7%), the anti-Xa peak was lower than the prophylactic range. There were differences among the anti-Xa groups with respect to some ROTEM parameters. No VTE was detected among the study subjects. In 3 subjects (4.9%), there were signs of bleeding, and these patients presented with longer thrombin times.ConclusionAnti-Xa values may be within the prophylactic range in slightly more than half of the critically ill patients receiving enoxaparin at prophylactic doses. The dosing of low-molecular-weight heparin (LMWH) in critically ill patients may require individualization based on anti-Xa. Further studies are therefore required to establish a universal anti-Xa prophylactic range for LMWH, the timing of anti-Xa determination, and management of LMWH dosing.https://www.frontiersin.org/articles/10.3389/fphar.2024.1498188/fullantifactor Xa activityintensive care unitlow-molecular-weight heparinpharmacodynamicsrotational thromboelastometryenoxaparin |
| spellingShingle | Piotr F. Czempik Piotr F. Czempik Artur Beberok Effect of prophylactic doses of enoxaparin on antifactor Xa activity confirmed by rotational thromboelastometry in critically ill patients: a preliminary prospective cohort study Frontiers in Pharmacology antifactor Xa activity intensive care unit low-molecular-weight heparin pharmacodynamics rotational thromboelastometry enoxaparin |
| title | Effect of prophylactic doses of enoxaparin on antifactor Xa activity confirmed by rotational thromboelastometry in critically ill patients: a preliminary prospective cohort study |
| title_full | Effect of prophylactic doses of enoxaparin on antifactor Xa activity confirmed by rotational thromboelastometry in critically ill patients: a preliminary prospective cohort study |
| title_fullStr | Effect of prophylactic doses of enoxaparin on antifactor Xa activity confirmed by rotational thromboelastometry in critically ill patients: a preliminary prospective cohort study |
| title_full_unstemmed | Effect of prophylactic doses of enoxaparin on antifactor Xa activity confirmed by rotational thromboelastometry in critically ill patients: a preliminary prospective cohort study |
| title_short | Effect of prophylactic doses of enoxaparin on antifactor Xa activity confirmed by rotational thromboelastometry in critically ill patients: a preliminary prospective cohort study |
| title_sort | effect of prophylactic doses of enoxaparin on antifactor xa activity confirmed by rotational thromboelastometry in critically ill patients a preliminary prospective cohort study |
| topic | antifactor Xa activity intensive care unit low-molecular-weight heparin pharmacodynamics rotational thromboelastometry enoxaparin |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1498188/full |
| work_keys_str_mv | AT piotrfczempik effectofprophylacticdosesofenoxaparinonantifactorxaactivityconfirmedbyrotationalthromboelastometryincriticallyillpatientsapreliminaryprospectivecohortstudy AT piotrfczempik effectofprophylacticdosesofenoxaparinonantifactorxaactivityconfirmedbyrotationalthromboelastometryincriticallyillpatientsapreliminaryprospectivecohortstudy AT arturbeberok effectofprophylacticdosesofenoxaparinonantifactorxaactivityconfirmedbyrotationalthromboelastometryincriticallyillpatientsapreliminaryprospectivecohortstudy |